Roche Holding AG CEO Net Worth

Last Updated Mar 10, 2025
CEO NameThomas Schinecker
NationalityGermany
Net Worth Estimation$30 million

Thomas Schinecker's estimated net worth of around $30 million is primarily attributed to his executive compensation, stock grants, and performance-based bonuses at Roche Holding AG, as well as his long-standing career within the pharmaceutical industry. This valuation also considers his holdings in Roche shares and related company benefits.

Thomas Schinecker's estimated net worth of $30,000,000 places him at 25% of the maximum and 33.3% above the minimum CEO net worth in the healthcare category provided. This suggests his wealth is well within the upper third of the specified range for CEOs in this sector.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Thomas Schinecker Performance in Roche Holding AG

Thomas Schinecker, CEO of Roche Holding AG, demonstrates strategic leadership by driving innovation and digital transformation in pharmaceutical development. His decisive approach emphasizes patient-centric solutions and operational efficiency, boosting the company's market presence and R&D productivity. Under Schinecker's tenure, Roche has strengthened its competitive position through enhanced pipeline development and global expansion, significantly increasing shareholder value.


Latest News

Roche Holding AG Reports Strong 2025 Growth and Strategic Acquisitions

Roche achieved 7% sales growth in the first nine months of 2025, with CEO Thomas Schinecker confirming no job cuts and a healthy business outlook, despite market challenges. The company also advanced its pipeline through major deals, including the acquisition of 89bio and a $1B+ bispecific antibody partnership.
Source: http://www.roche.com/media/releases/med-cor-2025-10-23



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Roche Holding AG are subject to change from time to time.

Comments

No comment yet